For example, for carriers of MLH1 pathogenic variants, there is a ten-fold increase in the risk of developing gastric and small bowel cancer, although this risk is not as high as for other previously mentioned cancer types, 5–7% and 0.4–11%, respectively [63,64,67,68]. Here, MLH1 is linked to small intestine carcinoma.